大血管病变和单支冠状动脉病变患者药物洗脱支架的临床和血管造影结果。

Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.

机构信息

Division of Cardiology, Department of Internal Medicine, Inje University Busan Baik Hospital, South Korea.

出版信息

Clin Cardiol. 2010 Jun;33(6):340-4. doi: 10.1002/clc.20744.

DOI:10.1002/clc.20744

PMID:20556803

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6653130/

Abstract

BACKGROUND

The aim of this study was to evaluate and compare the clinical and angiographic outcomes of 3 drug-eluting stents (DES) in patients with large vessel diameter and single coronary artery lesions.

HYPOTHESIS

The efficacy of 3 DESs may be similar.

METHODS

A total of 411 consecutive patients who visited 3 university hospitals from June 2004 to December 2007 and had a single coronary lesion which was treated with the use of a DES that was 3.5 mm in diameter were enrolled in this study. Patients were divided into 3 stent groups: Paclitaxel-eluting stent (PES, n = 105), Sirolimus-eluting stent (SES, n = 259), and Zotarolimus-eluting stent (ZES, n = 47). The study end point was a composite of major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), and ischemia-driven target-vessel revascularization (TVR) for 12 months.

RESULTS

Baseline characteristics were not different. Late loss was higher in the ZES group than the other stents (0.5 +/- 0.4 mm in SES vs 0.3 +/- 0.5 mm in PES, 0.7 +/- 0.5 mm in ZES, P = 0.001). The total MACE-free survival rate was not significantly different between the SES group and the PES group (98.8% in SES vs 97.1% in PES, P = 0.252) or the PES group and the ZES group (97.1% in PES vs 93.6% in ZES, P = 0.301). However, the SES group showed a significantly better MACE-free survival rate compared with the ZES group (98.8% in SES vs 93.6% in ZES, P = 0.018).

CONCLUSIONS

Clinical and angiographic outcomes of DES in a large vessel diameter and single coronary artery is excellent and SES appears to show better angiographic and clinical outcomes than ZES.

摘要

背景

本研究旨在评估和比较 3 种药物洗脱支架（DES）在大血管直径和单支冠状动脉病变患者中的临床和血管造影结果。

假说

3 种 DES 的疗效可能相似。

方法

本研究共纳入 411 例 2004 年 6 月至 2007 年 12 月期间在 3 所大学医院就诊的连续患者，这些患者均患有单支冠状动脉病变，采用直径为 3.5mm 的 DES 进行治疗。患者被分为 3 个支架组：紫杉醇洗脱支架（PES，n=105）、西罗莫司洗脱支架（SES，n=259）和佐他莫司洗脱支架（ZES，n=47）。研究终点是 12 个月时主要不良心脏事件（MACE）的复合终点，包括心脏死亡、心肌梗死（MI）和缺血驱动的靶血管血运重建（TVR）。

结果

基线特征无差异。ZES 组的晚期丢失高于其他支架（SES 组为 0.5±0.4mm，PES 组为 0.3±0.5mm，ZES 组为 0.7±0.5mm，P=0.001）。SES 组与 PES 组（SES 组为 98.8%，PES 组为 97.1%，P=0.252）或 PES 组与 ZES 组（PES 组为 97.1%，ZES 组为 93.6%，P=0.301）之间的总 MACE 无事件生存率无显著差异。然而，SES 组的 MACE 无事件生存率明显优于 ZES 组（SES 组为 98.8%，ZES 组为 93.6%，P=0.018）。